GLP-1 and Oral Health

Glucagon-like peptide-1 (GLP-1) receptor agonists—commonly prescribed for type 2 diabetes and weight management—have become increasingly popular in recent years. Medications such as semaglutide and tirzepatide improve blood sugar control and promote weight loss by slowing gastric emptying, reducing appetite, and enhancing insulin secretion. While these systemic benefits are significant, GLP-1 medications can also influence oral health in several ways.

One of the most common side effects is dry mouth (xerostomia). Reduced salivary flow increases the risk of dental caries, gum inflammation, and oral infections because saliva plays a critical protective role in buffering acids and washing away bacteria. Nausea and occasional vomiting, also reported with GLP-1 therapy, may expose teeth to gastric acid, contributing to enamel erosion over time. Patients experiencing appetite suppression may also change eating patterns—sometimes consuming smaller, more frequent meals—which can increase acid challenges to enamel if oral hygiene is inconsistent.

On the positive side, improved glycemic control benefits periodontal health. Elevated blood glucose is strongly associated with gum disease, and better metabolic regulation can reduce inflammation and improve healing.

For patients taking GLP-1 medications, preventive strategies—adequate hydration, fluoride use, regular dental visits, and careful monitoring of oral symptoms—are essential to maintaining long-term oral health.